ASTRAZENECA PLC (AZN) Form 6-K — Sep 1, 2026
AstraZeneca announced positive high-level results from the SANOVO Phase III trial, in which Tagrisso (osimertinib) plus Orpathys (savolitinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival versus Tagrisso alone in treatment-naive patients with MET-overexpressing EGFR-mutated advanced lung cancer. The PFS benefit was shown in both the high MET (IHC 3+) and intention-to-treat populations, with encouraging clinical benefit in overall survival as a secondary endpoint, and the safety profile was consistent with the known profiles of each medicine with no new safety findings.
Key figures
- Dosing
- Tagrisso 80mg once daily plus Orpathys or placebo at 300/200mg twice daily (body-weight based)
- Safety
- Consistent with known profiles of each medicine; no new safety findings
- Os status
- Encouraging clinical benefit as secondary endpoint; follow-up ongoing
- Trial name
- SANOVO (Phase III, China)
- Patients randomized
- 326
- Randomization ratio
- 1:1
- Primary endpoint status
- PFS met — statistically significant and highly clinically meaningful improvement
- Populations with benefit
- ["high MET (IHC 3+)","intention-to-treat (IHC 2+ and IHC 3+)"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.